Sp111
RECENT ADVANCES IN PREDICTION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND CIRRHOSIS: INSIGHTS FROM THE GUT MICROBIOME
Date
May 18, 2024
Explore related products in the following collection:
Presenter
University of California San Diego
Tracks
Related Products
LEAN, OVERWEIGHT AND OBESE MASLD PATIENTS HAVE SIMILAR AMOUNTS OF FIBROSIS THAT IS ASSOCIATED WITH POLYGENIC RISK
BACKGROUND AND AIMS: There is conflicting data on the risk of fibrosis and liver-related outcomes in patients with lean MASLD and the role of genetic testing in this population…
ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…
